Major M&A activity this week includes Amazon's $11.6 billion acquisition of Globalstar to accelerate its satellite internet business, Instacart's purchase of Colombian grocery tech firm Instaleap, and Avanos Medical's $1.3 billion acquisition by American Industrial Partners. Meanwhile, several companies filed for bankruptcy including QVC (over $5 billion debt), Freedom Forever (solar company), and Spirit Airlines continues to struggle.

Kailera Therapeutics completed the largest biotech IPO since 2021, raising $625 million at $16 per share. The company is developing GLP-1-based obesity treatments, with its lead candidate ribupatide in Phase 3 trials. Kailera enters a competitive $200 billion obesity market dominated by Eli Lilly and Novo Nordisk, with promising early data showing up to 12.1% weight loss in oral formulation trials.

Eli Lilly's newly launched obesity pill recorded 1,390 prescriptions in its first week, showing slower initial uptake compared to Novo Nordisk's oral Wegovy, which achieved 3,071 prescriptions in its first four days. Novo Nordisk maintains market leadership with 113,354 weekly prescriptions for Wegovy, demonstrating continued strong demand in the competitive oral obesity drug segment.

China's diabetes devices market is projected to grow from USD 7.19 billion in 2025 to USD 14.51 billion by 2034, with a CAGR of 8.11%. Growth is driven by rising diabetes prevalence (118 million patients), aging population, government healthcare reforms, and technological advancements in glucose monitoring and insulin delivery systems. Key challenges include cost sensitivity and uneven reimbursement coverage across regions.

Viking Therapeutics is a biotech company developing weight loss drugs in the GLP-1 class, with injectable VK2735 in phase 3 trials and an oral candidate entering phase 3 in Q3 2026. The obesity drug market is projected to reach $100 billion by decade's end, currently dominated by Eli Lilly and Novo Nordisk. While Viking stock has shown volatility and room to run from current levels, the article cautions that a single stock is unlikely to make investors millionaires, but could be a valuable addition to a diversified portfolio.

Over 100 pharmaceutical companies are competing to develop 120+ pipeline drugs for non-small cell lung cancer (NSCLC), with approximately 30+ drugs in late-stage development. The competitive landscape is driven by precision oncology advances, including next-generation targeted agents and immunotherapy combinations. Recent FDA approvals and designations highlight innovation in treating EGFR-mutated, ALK-positive, and other biomarker-selected NSCLC populations.

MeiraGTx reacquired bota-vec, a treatment for X-linked retinitis pigmentosa (XLRP), from Johnson & Johnson for a $25 million upfront payment. The company raised $100 million through a share offering and plans to expedite regulatory filings for U.S. and EU approval with a potential 2027 launch. Three-year data from its xerostomia treatment showed durable benefits. Stock declined 15.8% on the announcement.

Eli Lilly announced a $6.3 billion acquisition of U.K.-based Centessa Pharmaceuticals, a clinical-stage biotech focused on neuroscience. The deal includes up to $1.5 billion in milestone payments tied to Centessa's lead drug candidate cleminorexton for sleep-wake disorders. Despite the large price tag, Lilly's stock reacted positively due to the company's strong financial position, bolstered by the success of weight-loss drugs Zepbound and Mounjaro. The acquisition represents Lilly's strategy of both building and acquiring assets for continued growth.

Eli Lilly's oral weight loss drug Foundayo (orforglipron) successfully met cardiovascular safety goals in the Phase 3 ACHIEVE-4 trial, demonstrating non-inferior risk of major adverse cardiovascular events compared to insulin glargine. The drug showed superior efficacy in reducing blood sugar and body weight, with a 57% lower risk of all-cause death. Lilly plans to submit the drug for FDA approval by Q2 2026, though the FDA previously requested additional clinical trials to address concerns about potential liver injury and gastric emptying.

Eli Lilly has captured 60% of the U.S. weight loss drug market, surpassing Novo Nordisk's 39% share, driven by superior clinical results and manufacturing investments. The company's tirzepatide-based drugs (Zepbound and Mounjaro) generated over $11 billion in recent quarterly revenue. However, the author predicts that retatrutide, a triple-pathway hormone agonist candidate showing 28% body weight reduction in trials, could further cement Lilly's market leadership by offering superior efficacy compared to current treatments.

Eli Lilly has significantly outperformed Novo Nordisk over the past three years, with Eli Lilly reaching a $1 trillion market cap while Novo Nordisk's value has declined. Eli Lilly's weight-loss drug Zepbound proved more effective than Novo Nordisk's Wegovy in clinical trials, and Eli Lilly has a stronger pipeline with candidates like retatrutide showing impressive results. While Eli Lilly maintains its market leadership, Novo Nordisk's stock may offer value at current valuations with potential upside from its deep pipeline.

GoodRx Holdings shares rose 2.69% as the company expanded access to Novo Nordisk's Wegovy HD, a higher-dose GLP-1 treatment for self-pay patients priced at $399 per month. The expansion reflects growing demand for GLP-1 obesity treatments and GoodRx's efforts to simplify medication access. The company also recently expanded access to Eli Lilly's oral GLP-1 medication Foundayo and Zepbound.